Summary: In 530 patients hospitalised for acute heart failure, empagliflozin 10 mg started in hospital once clinically stable produced more clinical benefit at 90 days than placebo on a hierarchical composite of death, heart failure events and symptom score (stratified win ratio 1.36; 95% CI 1.09 to 1.68). Benefit was seen regardless of ejection fraction or diabetes status.
PICO Summary
| Element | Detail |
|---|---|
| Population | 530 patients hospitalised with acute de novo or decompensated chronic heart failure, regardless of left ventricular ejection fraction, with or without diabetes; multinational, double-blind, randomised, placebo-controlled trial; randomised in hospital when clinically stable (median 3 days from admission). |
| Intervention | Empagliflozin 10 mg once daily for up to 90 days. |
| Comparison | Placebo for up to 90 days. |
| Outcome | Clinical benefit at 90 days, a hierarchical composite of death from any cause, number of heart failure events, time to first heart failure event, and a difference of 5 points or more in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score: stratified win ratio 1.36 (95% CI 1.09 to 1.68); p=0.0054. Benefit was observed in acute de novo and in decompensated chronic heart failure, and regardless of ejection fraction or diabetes. Serious adverse events: 32.3% vs 43.6%. |
Expert Commentary
My verdict is positive. EMPULSE asked whether empagliflozin can be started during an admission for acute heart failure. In 530 patients randomised once clinically stable, a median of 3 days after admission, more of those given empagliflozin had clinical benefit at 90 days (stratified win ratio 1.36; 95% CI 1.09 to 1.68). The benefit was seen in new and in decompensated chronic heart failure, and regardless of ejection fraction or diabetes. Serious adverse events were reported in 32.3% on empagliflozin and 43.6% on placebo, so starting in hospital did not appear to cause harm. The limitation lies in the endpoint. A win ratio on a hierarchical composite mixes death, heart failure events and a 5-point difference in a symptom score, and the abstract does not show how much each tier contributed. It cannot be told from the abstract whether fewer patients died or more simply felt better. The trial was also short and small. Can I use this with my patients? Yes. For a patient admitted with acute heart failure who has stabilised, I would start empagliflozin 10 mg before discharge instead of leaving the decision to the clinic. I would like to see the component results, and a larger trial powered for death and readmission.
References
Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1. PMID: 35228754.

